The Care Notebook

When thymalfasin comes up

Red-flag notes

A research label does not make it care.

The mix-up

Myth: A research-use label creates a shortcut to legitimate treatment.

The answer

The FDA, the US medicine regulator, says a label claiming a product is only for research is not the whole story. It also looks at the offer to decide whether the product is being sold as a drug for people. This was checked on September 26, 2026.

Read what is being offered around the label

In warning letters dated March and August 2026, the FDA described water sold for dissolving research-labelled products to prepare a shot. Selling them together was a sign, it said, that the products were meant for people to inject.

The letters make the FDA's claims about specific businesses; they are not court rulings.

For care, ask a doctor or another licensed health worker who treats patients to review your health and explain the exact product. Do not treat research wording as a care plan.

FDA letter on research labels FDA letter on intended use

Look for an actual prescription process

Under federal law, a prescription medicine cannot be handed over until there is a valid prescription, as of September 26, 2026.

The FDA lists offers without a prescription among its warning signs for online pharmacies.

FDA: how to check a pharmacy on the internet

Challenge claims of official approval

As of September 28, 2026, describing a US thymosin alpha-1 product as FDA-approved is false.

The FDA says a real patient need for compounding does not give the resulting medicine FDA approval.

FDA record on this peptide FDA explanation of approval claims

Pause at unusual payment demands

In its July 2026 alert, the Federal Trade Commission warns that demands to pay only by wire, bank transfer, cryptocurrency, payment app or gift card can signal a scam.

Cryptocurrency is digital money. Ask for clear payment and cancellation terms before paying anything.

Federal Trade Commission payment alert

Choose a different note